Poniard Pharmaceuticals, Inc.
OTC: PARD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert F. Caspari
- Employees
- 7
- Headquarters
- Seattle, United States
- IPO year
- 1988
- Market cap
- $150.0
- Website
- http://www.poniard.com
Loading PARD…
Loading profile data…Frequently asked questions about PARD
What does Poniard Pharmaceuticals, Inc. (PARD) do?
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin throu...
Where does PARD trade?
Poniard Pharmaceuticals, Inc. (PARD) trades on the Other OTC.
What sector is PARD in?
Poniard Pharmaceuticals, Inc. (PARD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Poniard Pharmaceuticals, Inc.?
Robert F. Caspari is the chief executive officer of Poniard Pharmaceuticals, Inc. (PARD).
Where is Poniard Pharmaceuticals, Inc. headquartered?
Poniard Pharmaceuticals, Inc. is headquartered in United States.
Does PARD pay a dividend?
Poniard Pharmaceuticals, Inc. (PARD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PARD go public?
Poniard Pharmaceuticals, Inc. (PARD) completed its initial public offering in 1988.